DE60112729D1 - Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion - Google Patents

Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion

Info

Publication number
DE60112729D1
DE60112729D1 DE60112729T DE60112729T DE60112729D1 DE 60112729 D1 DE60112729 D1 DE 60112729D1 DE 60112729 T DE60112729 T DE 60112729T DE 60112729 T DE60112729 T DE 60112729T DE 60112729 D1 DE60112729 D1 DE 60112729D1
Authority
DE
Germany
Prior art keywords
dion
thiazolidine
pyridyl
ethoxy
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112729T
Other languages
English (en)
Other versions
DE60112729T2 (de
Inventor
Andrew Simon Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60112729D1 publication Critical patent/DE60112729D1/de
Application granted granted Critical
Publication of DE60112729T2 publication Critical patent/DE60112729T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60112729T 2000-03-14 2001-03-14 Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion Expired - Lifetime DE60112729T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0006133 2000-03-14
GBGB0006133.3A GB0006133D0 (en) 2000-03-14 2000-03-14 Novel pharmaceutical
PCT/GB2001/001131 WO2001068646A1 (en) 2000-03-14 2001-03-14 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
DE60112729D1 true DE60112729D1 (de) 2005-09-22
DE60112729T2 DE60112729T2 (de) 2006-06-08

Family

ID=9887600

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112729T Expired - Lifetime DE60112729T2 (de) 2000-03-14 2001-03-14 Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion

Country Status (31)

Country Link
US (2) US7074811B2 (de)
EP (1) EP1265893B1 (de)
JP (1) JP2003527393A (de)
KR (1) KR100746813B1 (de)
CN (1) CN100516062C (de)
AP (1) AP1545A (de)
AT (1) ATE302202T1 (de)
AU (1) AU777987B2 (de)
BG (1) BG65924B1 (de)
BR (1) BR0108870A (de)
CA (1) CA2403109A1 (de)
CZ (1) CZ20023074A3 (de)
DE (1) DE60112729T2 (de)
DK (1) DK1265893T3 (de)
DZ (1) DZ3316A1 (de)
EA (1) EA005115B1 (de)
ES (1) ES2243458T3 (de)
GB (1) GB0006133D0 (de)
HK (1) HK1052502A1 (de)
HU (1) HUP0300158A3 (de)
IL (2) IL151425A0 (de)
MA (1) MA25658A1 (de)
MX (1) MXPA02008972A (de)
NO (1) NO323448B1 (de)
NZ (1) NZ520910A (de)
OA (1) OA12229A (de)
PL (1) PL357283A1 (de)
SK (1) SK286399B6 (de)
UA (1) UA73974C2 (de)
WO (1) WO2001068646A1 (de)
ZA (1) ZA200207292B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002343050A1 (en) * 2001-11-21 2003-06-10 Smithkline Beecham P.L.C. 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (de) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3468562A1 (de) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120078A (en) * 1871-10-17 Improvement in revolving flower-stands
US137940A (en) * 1873-04-15 Improvement in elevators
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
JP2002504137A (ja) 1997-06-18 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) * 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909075D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
EP1175418A2 (de) 1999-04-23 2002-01-30 Smithkline Beecham Plc Thiazolidindionderivat und seine verwendung als antidiabetikum
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
HU225919B1 (en) 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
MXPA02008972A (es) 2003-02-10
WO2001068646A1 (en) 2001-09-20
HK1052502A1 (en) 2003-09-19
ATE302202T1 (de) 2005-09-15
ZA200207292B (en) 2003-05-06
PL357283A1 (en) 2004-07-26
SK13302002A3 (sk) 2003-02-04
BG107012A (bg) 2003-04-30
JP2003527393A (ja) 2003-09-16
CN100516062C (zh) 2009-07-22
HUP0300158A3 (en) 2005-04-28
ES2243458T3 (es) 2005-12-01
DZ3316A1 (de) 2001-09-20
AP1545A (en) 2006-01-12
CN1358184A (zh) 2002-07-10
CZ20023074A3 (cs) 2003-02-12
OA12229A (en) 2003-11-07
AU4084301A (en) 2001-09-24
MA25658A1 (fr) 2002-12-31
IL151425A0 (en) 2003-04-10
AP2002002600A0 (en) 2002-09-30
KR20020079998A (ko) 2002-10-21
HUP0300158A2 (en) 2003-05-28
DK1265893T3 (da) 2005-11-14
NO20024307D0 (no) 2002-09-09
EP1265893B1 (de) 2005-08-17
EP1265893A1 (de) 2002-12-18
EA200200975A1 (ru) 2003-02-27
NO20024307L (no) 2002-09-09
NO323448B1 (no) 2007-05-07
BG65924B1 (bg) 2010-05-31
GB0006133D0 (en) 2000-05-03
UA73974C2 (en) 2005-10-17
US7074811B2 (en) 2006-07-11
US20050267162A1 (en) 2005-12-01
IL151425A (en) 2009-08-03
BR0108870A (pt) 2002-12-17
KR100746813B1 (ko) 2007-08-06
NZ520910A (en) 2004-06-25
AU777987B2 (en) 2004-11-11
US20040152901A1 (en) 2004-08-05
SK286399B6 (sk) 2008-09-05
DE60112729T2 (de) 2006-06-08
CA2403109A1 (en) 2001-09-20
EA005115B1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
DE60112729D1 (de) Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion
DE60004196D1 (de) Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
NO20031356L (no) Nye polymorfe former av 5-[4-[2-[N-metyl-N-(2- pyridyl]amino]etoksy]benzyl]tiazolidin-2,4-dionmaleat og fremgangsmåte for fremstilling avsamme
NO20003069L (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
NO20031020D0 (no) Hydrokloridsalt av 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
DK1349855T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
NO20025882L (no) 5-(4-(2-(N-metyl-N-(2-pyridyl)amino)etoksy)benzyl)-tiazolidin- 2,4-dion hydriodid som farmasöytisk middel
HRP20030068B1 (en) Tartrate salt of thiazolidinedione derivative
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona
SI1173435T1 (en) Polymorph of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleic acid salt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition